Project Grant K99HL175098
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$101K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), will support research to characterize the role of the alternative complement pathway in the development of acute chest syndrome (ACS) in sickle cell disease (SCD). The award to Emory University, totaling $1,414,152, will run from August 1, 2024 to July 31, 2029. The key objectives are to define the mechanisms by which complement...
This federal Project Grant award of $827,753.90, awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the role of thiol isomerases in promoting redox-sensitive vaso-occlusion in sickle cell disease (SCD). The award enables the awardee, Bloodworks, an independent nonprofit organization in Seattle, to conduct a multi-year research project focused on mechanistically examining how thiol...
The University of Illinois received a $607,535 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award, effective September 17, 2024 through August 31, 2025, supports research to evaluate the effects of hemin, a breakdown product of cell-free hemoglobin, on the pulmonary endothelium and its contribution to the acute and chronic pulmonary complications of sickle cell disease. The research aims to...
This federal Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837), is focused on characterizing the role of Factor XII (FXII) in the thrombo-inflammatory complications of sickle cell disease. The total award amount is $1,449,454.00 with a project period from July 15, 2024 to June 30, 2028. The key objectives are to: 1) identify disease-specific triggers of FXII activation, 2) characterize FXII's...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $637,526 to Duke University to conduct research on the effects of sickle red blood cells (RBCs) on neutrophil activation and phenotypes in sickle cell disease. The research aims to delineate the specific characteristics of sickle RBCs that induce neutrophil activation, as well as the downstream consequences of these sickle...
This Project Grant award of $765,622 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop orally bioavailable degraders of two fetal hemoglobin gene repressors to elevate HbF levels and treat sickle cell disease (SCD). The award benefits from the expertise of the collaborating research teams at Yale University and Children's Hospital of Philadelphia. The Yale team will lead the overall project, while the...
This federal Project Grant award, valued at $179,280, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant aims to investigate how early life nutritional stress, particularly exposure to high-fat diet, impacts neutrophil development and function in the context of sickle cell disease (SCD). The research under this award seeks to evaluate the correlation between diet, disease severity, and neutrophil...
This $469,500 Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), aims to assess the safety of different hormonal contraceptive methods for individuals with sickle cell disease. The key products and services to be delivered include: Using health system data to compare the risk of sickle cell disease complications (e.g., venous thromboembolism, stroke) for individuals...
This $299,790 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of novel allosteric modulators of the thrombin receptor, protease-activated receptor 1 (PAR1), called Parmodulins, for the treatment of sickle cell disease (SCD). The project aims to identify optimized Parmodulins with improved potency and oral activity, and confirm their efficacy in mouse models of SCD, including...
This $445,000 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) supports research to characterize the role of neutrophil extracellular traps (NETs) in immune homeostasis and explore the potential of NET-directed therapeutics for thromboinflammatory diseases. The three specific aims of the project are: 1) to clarify the role of NETs in host defense, 2) to define the mechanisms by which platelet factor...